New Data Supports Biological Rationale for DMX-200 in FSGS

• New data presented at Kidney Week 2026 supports DMX-200's mechanism of action in FSGS
• Study found elevated CCR2 activity linked to poorer kidney outcomes in FSGS patients
• Findings reinforce the rationale for DMX-200's development in the ACTION3 Phase 3 trial
• Dimerix filed a provisional patent application based on the new findings

Dimerix Ltd, a clinical-stage biopharmaceutical company, announced new translational research findings presented at Kidney Week 2026, providing further independent evidence supporting its Phase 3 investigational therapy, DMX-200, for focal segmental glomerulosclerosis (FSGS). The findings demonstrated that activation of the MCP-1/CCR2 inflammatory pathway is associated with disease progression and poorer outcomes in patients with FSGS, further supporting CCR2 as a therapeutic target. The research utilized data from the Nephrotic Syndrome Study Network (NEPTUNE), one of the largest nephrotic syndrome research cohorts in North America. The study identified elevated activation of the MCP-1/CCR2 inflammatory signalling pathway in patients with FSGS, and demonstrated associations between CCR2 pathway activation, kidney function decline and disease progression. These findings are the subject of a newly filed Dimerix provisional patent application and may provide additional support for potential regulatory filings for DMX-200, subject to success in the ACTION3 Phase 3 trial.